SE36/cVLP is a next-generation blood-stage malaria vaccine candidate based on the N-terminal domain of the P. falciparum SERA5 antigen. The SE36 antigen has previously been tested in phase I clinical trials in combination with two different adjuvants. The SE36/cVLP construct has also been produced in lab-scale batches and showed high immunogenicity in preclinical rat models.